drugset / Trial / NCT05888857
MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.
Phase 2
Not yet recruiting
102 enrolled
Institut Bergonié
AstraZeneca · collabNational Cancer Institute, France · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Multicentric, prospective, multi-indication, single-treatment arm, open-label phase II trial assessing the efficacy of MEDI5752
Timeline
- Start
- 2025-09
- Primary completion
- 2026-03
- Completion
- 2028-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Volrustomig | Monoclonal antibody | — | Intravenous |
Indications
No indication recorded.